As of 2025-05-16, the EV/EBITDA ratio of Lexicon Pharmaceuticals Inc (LXRX) is -1.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LXRX's latest enterprise value is 226.13 mil USD. LXRX's TTM EBITDA according to its financial statements is -184.29 mil USD. Dividing these 2 quantities gives us the above LXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.2x - 13.3x | 13.1x |
| Forward P/E multiples | 19.5x - 29.7x | 20.2x |
| Fair Price | (9.98) - (6.86) | (8.54) |
| Upside | -1982.5% - -1394.7% | -1711.6% |
| Date | EV/EBITDA |
| 2025-05-13 | -1.42 |
| 2025-05-12 | -1.51 |
| 2025-05-09 | -1.56 |
| 2025-05-08 | -1.54 |
| 2025-05-07 | -1.53 |
| 2025-05-06 | -1.48 |
| 2025-05-05 | -1.60 |
| 2025-05-02 | -1.52 |
| 2025-05-01 | -1.61 |
| 2025-04-30 | -1.62 |
| 2025-04-29 | -1.50 |
| 2025-04-28 | -1.54 |
| 2025-04-25 | -1.58 |
| 2025-04-24 | -1.57 |
| 2025-04-23 | -1.51 |
| 2025-04-22 | -1.44 |
| 2025-04-21 | -1.32 |
| 2025-04-17 | -1.19 |
| 2025-04-16 | -1.17 |
| 2025-04-15 | -1.19 |
| 2025-04-14 | -1.23 |
| 2025-04-11 | -1.19 |
| 2025-04-10 | -1.16 |
| 2025-04-09 | -1.15 |
| 2025-04-08 | -1.17 |
| 2025-04-07 | -1.20 |
| 2025-04-04 | -1.01 |
| 2025-04-03 | -1.06 |
| 2025-04-02 | -1.17 |
| 2025-04-01 | -1.10 |
| 2025-03-31 | -1.09 |
| 2025-03-28 | -1.31 |
| 2025-03-27 | -0.87 |
| 2025-03-26 | -0.83 |
| 2025-03-25 | -0.89 |
| 2025-03-24 | -0.90 |
| 2025-03-21 | -0.90 |
| 2025-03-20 | -0.86 |
| 2025-03-19 | -0.89 |
| 2025-03-18 | -0.89 |
| 2025-03-17 | -0.94 |
| 2025-03-14 | -0.90 |
| 2025-03-13 | -0.89 |
| 2025-03-12 | -0.93 |
| 2025-03-11 | -0.89 |
| 2025-03-10 | -0.88 |
| 2025-03-07 | -0.95 |
| 2025-03-06 | -0.91 |
| 2025-03-05 | -0.84 |
| 2025-03-04 | -0.82 |